- Home
- GROV vs TARA Comparison
GROV vs TARA Comparison
Compare GROV & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GROV | TARA |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.1M | 236.1M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GROV | TARA |
|---|---|---|
| Price | $1.01 | $3.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.60 | ★ $24.40 |
| AVG Volume (30 Days) | 86.9K | ★ 324.4K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.26 | 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $173,716,000.00 | $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.86 | $3.02 |
| 52 Week High | $1.57 | $7.82 |
Technical Indicators
Market Signals| Indicator | GROV | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 49.08 |
| Support Level | $0.86 | $3.73 |
| Resistance Level | $1.15 | $4.17 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 61.95 | 57.58 |
Price Performance
Historical ComparisonAbout GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.